Sign In

Login

Password

Forgot Password ? Sign Up

Nilotinib (Spanish Wikipedia)

Analysis of information sources in references of the Wikipedia article "Nilotinib" in Spanish language version.

refsWebsite
Global rank Spanish rank
10nih.gov
4th place
4th place
9doi.org
2nd place
2nd place
2web.archive.org
1st place
1st place
2fda.gov
447th place
668th place
1tasigna.com
low place
low place
1cancer.gov
1,684th place
1,021st place
1drugs.com
399th place
648th place
1europa.eu
68th place
91st place
1medicines.org.uk
3,823rd place
low place
1tga.gov.au
3,984th place
low place
1medscape.com
719th place
759th place
1huginonline.com
low place
low place
1medicalxpress.com
8,255th place
low place
1novartis.com
low place
low place

cancer.gov

doi.org

dx.doi.org

  • Manley, P.; Cowan-Jacob, S.; Mestan, J. (2005). «Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia». Biochimica et Biophysica Acta 1754 (1–2): 3-13. PMID 16172030. doi:10.1016/j.bbapap.2005.07.040. 
  • Manley, P.; Stiefl, N.; Cowan-Jacob, S.; Kaufman, S.; Mestan, J.; Wartmann, M.; Wiesmann, M.; Woodman, R. et al. (2010). «Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib». Bioorganic & Medicinal Chemistry 18 (19): 6977-6986. PMID 20817538. doi:10.1016/j.bmc.2010.08.026. 
  • Olivieri, A.; Manzione, L. (2007). «Dasatinib: a new step in molecular target therapy». Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 18 Suppl 6: vi42-vi46. PMID 17591830. doi:10.1093/annonc/mdm223. 
  • Breccia, M.; Alimena, G. (2010). «Nilotinib: a second-generation tyrosine kinase inhibitor for chronic myeloid leukemia». Leukemia research 34 (2): 129-134. PMID 19783301. doi:10.1016/j.leukres.2009.08.031. 
  • Kantarjian H et al.; Giles, Francis; Wunderle, Lydia; Bhalla, Kapil; O'Brien, Susan; Wassmann, Barbara; Tanaka, Chiaki; Manley, Paul; Rae, Patricia; Mietlowski, William; Bochinski, Kathy; Hochhaus, Andreas; Griffin, James D.; Hoelzer, Dieter; Albitar, Maher; Dugan, Margaret; Cortes, Jorge; Alland, Leila; Ottmann, Oliver G. (2006). «Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL». N Engl J Med 354 (24): 2542-51. PMID 16775235. doi:10.1056/NEJMoa055104. 
  • Khurana V, Minocha M, Pal D, Mitra AK (marzo de 2014). «Role of OATP-1B1 and/or OATP-1B3 in hepatic disposition of tyrosine kinase inhibitors.». Drug Metabol Drug Interact. 0 (0): 1-11. PMID 24643910. doi:10.1515/dmdi-2013-0062. 
  • Khurana V, Minocha M, Pal D, Mitra AK (mayo de 2014). «Inhibition of OATP-1B1 and OATP-1B3 by tyrosine kinase inhibitors.». Drug Metabol Drug Interact. 0 (0): 1-11. PMID 24807167. doi:10.1515/dmdi-2014-0014. 
  • Weisberg E, Manley P, Mestan J, Cowan-Jacob S, Ray A, Griffin JD (junio de 2006). «AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL». Br. J. Cancer 94 (12): 1765-9. PMC 2361347. PMID 16721371. doi:10.1038/sj.bjc.6603170. 
  • Manley, PW; Drueckes, P; Fendrich, G; Furet, P; Liebetanz, J; Martiny-Baron, G; Mestan, J; Trappe, J et al. (2010). «Extended kinase profile and properties of the protein kinase inhibitor nilotinib». Biochimica et Biophysica Acta 1804 (3): 445-53. PMID 19922818. doi:10.1016/j.bbapap.2009.11.008. 

drugs.com

europa.eu

ema.europa.eu

fda.gov

fda.gov

accessdata.fda.gov

huginonline.com

cws.huginonline.com

medicalxpress.com

medicines.org.uk

medscape.com

reference.medscape.com

nih.gov

ncbi.nlm.nih.gov

novartis.com

tasigna.com

tga.gov.au

ebs.tga.gov.au

web.archive.org